ITBMed AB is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about ITBMed AB. ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics primarily for organ transplantation and stem cell transplantation. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in revolutionizing the treatment of organ transplant patients, by allowing the complete discontinuation of all immunosuppressive drugs and restoration of a normal life.
Address
Sonja Kovalevskys Gata 4
Company size
11-50 employees
Headquarters
Stockholm, Stockholm County